Episode Summary
Executive Summary: Science Friday featured three segments: neuroscientist Mary Frances O’Connor on how grief is processed in the brain and why bereavement can affect health; Dr. Carl June on decade-long remission in two leukemia patients treated with CAR T cell therapy; and University of Oregon grad students on custom heated shorts for Olympic skiers. Together, the show highlighted how science can explain deeply human experiences and improve performance and treatment.
Main Topics: The neuroscience of grief vs. grieving: O’Connor distinguishes grief as the immediate emotional wave from grieving as the long-term adaptation process, arguing that the brain gradually rewires to accept a loved one’s absence. Brain, body, and memory in bereavement: The conversation explains that grief involves memory, self-other bonding, physiological regulation, and persistent expectations that the deceased may return, making it a whole-body experience. Treatment, diagnosis, and support for grief: The segment discusses prolonged grief disorder, the limits of antidepressants for grief-specific pain, the temporary nature of sleep problems, and the importance of social and professional support. COVID-19 and unequal grief burdens: O’Connor frames the pandemic as a mass-bereavement event, noting disrupted mourning rituals and emphasizing that grief is also a health disparity that disproportionately affects minority communities. CAR T cell therapy and long-term remission: Dr. June describes two chronic leukemia patients who remain cancer-free 10 years after receiving CAR T cells, calling the results evidence that the therapy can function as a durable cure in some blood cancers. Heated sports technology for Olympic performance: Graduate students Josh Daniel and Lauren Samuels explain how embroidered heating elements and batteries in custom shorts help Alpine skiers maintain leg warmth without adding bulky layers.
Key Arguments: Grief and grieving are not identical: grief is the acute emotional response, while grieving is the long process of adapting to loss without eliminating grief entirely. The brain must update its predictions after loss; it keeps expecting the loved one’s return until new neural patterns form through time and experience. Avoidance can prolong grief because it reduces opportunities for the brain to learn the new reality of the loss. Grief is not just psychological; it has bodily effects, including altered stress regulation and increased mortality risk after spousal loss. Major depressive disorder and grief are distinct, so antidepressants may help comorbid depression but do not resolve yearning or grief-specific pain. Sleep medications are often used after bereavement but may not be a good long-term solution; behavioral approaches like CBTI are preferable. COVID-19 created an unusually large and simultaneous wave of bereavement, while social distancing disrupted the normal cues and rituals that help people understand death. CAR T cell therapy can persist in the body for years, continuing immune surveillance and killing leukemia cells long after infusion. The new ski shorts show how athlete-centered design and embedded heating tech can improve warm-up routines and performance in extreme cold.
Data Points: Years studying grief: 22 years - Mary Frances O’Connor described the length of her research career First neuroscience grief study: First study of grief from a neuroscience perspective - O’Connor’s early fMRI work in graduate school Mortality risk after spouse loss (men): 2x higher for the first six months - She cited epidemiological research on the “broken heart” phenomenon COVID bereavement estimate: About 9 survivors per death - U.S. modeling of loved ones grieving each COVID death COVID deaths referenced: Close to 1 million - Used to estimate the scale of grief in the United States Children affected by COVID caregiver loss: 65% of those children are racial or ethnic minorities - Illustrating bereavement as a health disparity Widowhood gap (ages 65–74): 25% Black Americans vs 15% white Americans - Example of unequal bereavement burden CAR T patient follow-up: 10 years - Two leukemia patients remained in remission for a decade CAR T expansion: 1 CAR T cell became 1,000 in the patient - Described exponential in-body proliferation after infusion Tumor burden in two CAR T patients: 3 to 7 pounds - Amount of tumor present at treatment time CAR T approval year: August 2017 - FDA approval for pediatric and young adult leukemia Success rate in acute leukemia: 80–90% long-term remissions - Dr. June contrasted acute leukemia outcomes with chronic leukemia Success rate in chronic leukemia: About 30% - For the type of leukemia in the two long-term responders Improved chronic leukemia remission with combination therapy: 80–90% - When CAR T is combined with ibrutinib in some centers Solid tumors in overall cancer burden: 90% - Dr. June emphasized solid cancers as the major remaining challenge Timeframe to build shorts: 4 months - University of Oregon students developed the heated shorts rapidly Sport performance detail: Hundredths of a second matter - Why athletes avoid bulky extra layers during competition Heating system: Lithium-ion battery with embroidered heating element - Technical design of the Olympic ski shorts
Pivotal Quotes: "Grief is that wave that just knocks you off your feet, where grieving is how the feeling of grief changes over time without ever going away." — Mary Frances O'Connor: Her definition of grief versus grieving "The brain literally has to create new wiring to understand what's happening." — Mary Frances O'Connor: Explaining how the brain adapts after loss "These were the first two patients, and what we found... they have aged now for 10 years with no further leukemia." — Dr. Carl June: Describing the long-term remission results in the CAR T study
Implications: Listeners get a clearer scientific framework for bereavement, treatment, and support, while the CAR T findings show the power of durable cellular immunotherapy. The ski shorts segment underscores how targeted design can turn research into performance gains.